{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T12:09:27Z","timestamp":1794917367283,"version":"4.9.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ijrobp.2025.03.032","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T20:48:08Z","timestamp":1743540488000},"page":"228-237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Treatment of Oligometastatic Parenchymal Lesions in Ovarian Cancer With Stereotactic Ablative Radiation Therapy: A Multicenter Prospective Phase 2 Trial (MITO RT3\/RAD)"],"prefix":"10.1016","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0529-201X","authenticated-orcid":false,"given":"Gabriella","family":"Macchia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6676-1169","authenticated-orcid":false,"given":"Donato","family":"Pezzulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura","family":"Campitelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Lucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Draghini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Fodor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Roberto","family":"D'Agostino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittoria","family":"Balcet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinella","family":"Tamburo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Giaccherini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Tortoreto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonietta","family":"Augurio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edy","family":"Ippolito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida Di","family":"Stefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Fanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lella","family":"Petrella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savino","family":"Cilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cosentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanda","family":"Salutari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio Giuseppe","family":"Morganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonietta","family":"Gambacorta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Fagotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Pignata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Ferrandina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Deodato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2025.03.032_bib0001","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/annonc\/mdw663","article-title":"Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recurrent disease","volume":"28","author":"Wilson","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.032_bib0002","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): A double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.032_bib0003","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2025.03.032_bib0004","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S1470-2045(20)30061-9","article-title":"Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): Post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial","volume":"21","author":"Ledermann","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.032_bib0005","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ygyno.2023.04.002","article-title":"PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients","volume":"173","author":"Gauduchon","year":"2023","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.032_bib0006","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.annonc.2023.11.015","article-title":"ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: Pathology and molecular biology and early, advanced and recurrent disease","volume":"35","author":"Ledermann","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.032_bib0007","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ygyno.2024.07.006","article-title":"Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease after first-line chemotherapy: An ad hoc subgroup analysis of PRIMA\/ENGOT-OV26\/GOG-3012","volume":"189","author":"Kamrava","year":"2024","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.032_bib0008","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa2103294","article-title":"Randomized trial of cytoreductive surgery for relapsed ovarian cancer","volume":"385","author":"Harter","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2025.03.032_bib0009","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(21)00006-1","article-title":"Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): A multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Shi","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.032_bib0010","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1902626","article-title":"Secondary surgical cytoreduction for recurrent ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2025.03.032_bib0011","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.3390\/cancers14051152","article-title":"Stereotactic body radiation therapy in patients with oligometastatic disease: Clinical state of the art and perspectives","volume":"14","author":"Kinj","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ijrobp.2025.03.032_bib0012","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/ijgc-2024-005361","article-title":"Stereotactic radiotherapy for managing ovarian cancer oligoprogression under poly (ADP-ribose) polymerase inhibitors (PARPi)","volume":"34","author":"Durante","year":"2024","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ijrobp.2025.03.032_bib0013","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.ijrobp.2024.09.010","article-title":"Stereotactic body radiation therapy for oligoprogressive ovarian cancer patients treated during poly(ADP-ribose)-polymerase inhibitor maintenance: Efficacy and adverse events from the epimetheo retrospective study","volume":"121","author":"Macchia","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.03.032_bib0014","doi-asserted-by":"crossref","first-page":"e311","DOI":"10.1634\/theoncologist.2019-0309","article-title":"A large, multicenter, retrospective study on efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic ovarian cancer (MITO RT1 study): A collaboration of MITO, AIRO GYN, and MaNGO groups","volume":"25","author":"Macchia","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.ijrobp.2025.03.032_bib0015","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.ijrobp.2024.09.036","article-title":"Stereotactic ablative radiation therapy for oligometastatic ovarian cancer lymph node disease: The MITO-RT3\/RAD phase II trial","volume":"121","author":"Macchia","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.03.032_bib0016","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.ijrobp.2018.03.058","article-title":"Stereotactic body radiation therapy for oligometastatic ovarian cancer: A step toward a drug holiday","volume":"101","author":"Lazzari","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.03.032_bib0017","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1097\/IGC.0000000000001324","article-title":"Stereotactic body radiation therapy in oligometastatic ovarian cancer: A promising therapeutic approach","volume":"28","author":"Iftode","year":"2018","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ijrobp.2025.03.032_bib0018","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ccr.2005.07.014","article-title":"Engaging the vascular component of the tumor response","volume":"8","author":"Fuks","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ijrobp.2025.03.032_bib0019","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1038\/s41591-018-0232-2","article-title":"Radiotherapy induces responses of lung cancer to CTLA-4 blockade","volume":"24","author":"Formenti","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.ijrobp.2025.03.032_bib0020","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death","volume":"13","author":"Obeid","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.ijrobp.2025.03.032_bib0021","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.it.2018.06.001","article-title":"Immunological mechanisms responsible for radiation-induced abscopal effect","volume":"39","author":"Rodr\u00edguez-Ruiz","year":"2018","journal-title":"Trends Immunol"},{"key":"10.1016\/j.ijrobp.2025.03.032_bib0022","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1136\/ijgc-2021-002709","article-title":"Efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic\/persistent\/recurrent ovarian cancer: A prospective, multicenter phase II study (MITO-RT3\/RAD)","volume":"32","author":"Macchia","year":"2022","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ijrobp.2025.03.032_bib0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.ijrobp.2025.03.032_bib0024","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/1748-717X-7-164","article-title":"A single-institution study of stereotactic body radiotherapy for patients with unresectable visceral pulmonary or hepatic oligometastases","volume":"7","author":"Fumagalli","year":"2012","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.032_bib0025","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s10585-024-10301-6","article-title":"Stereotactic radiotherapy for liver oligometastases: A pooled analysis following the ESTRO\/EORTC consensus recommendations","volume":"41","author":"Pezzulla","year":"2024","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.ijrobp.2025.03.032_bib0026","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.jtho.2018.06.007","article-title":"Histology, tumor volume, and radiation dose predict outcomes in NSCLC patients after stereotactic ablative radiotherapy","volume":"13","author":"Shiue","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.032_bib0027","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.prro.2013.01.005","article-title":"Radiation dose responses for chemoradiation therapy of pancreatic cancer: An analysis of compiled clinical data using biophysical models","volume":"4","author":"Moraru","year":"2014","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.032_bib0028","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ygyno.2024.01.023","article-title":"Efficacy of stereotactic body radiotherapy and response prediction using artificial intelligence in oligometastatic gynaecologic cancer","volume":"184","author":"Macchia","year":"2024","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.032_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.110072","article-title":"Machine-learning prediction of treatment response to stereotactic body radiation therapy in oligometastatic gynecological cancer: A multi-institutional study","volume":"191","author":"Cilla","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.032_bib0030","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ijrobp.2023.04.025","volume":"117","author":"Macchia","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.03.032_bib0031","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s10585-024-10324-z","article-title":"Multi-institutional study using SBRT to treat mediastinal and hilar lymphadenopathy","volume":"42","author":"Caivano","year":"2024","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.ijrobp.2025.03.032_bib0032","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1136\/ijgc-2021-003237","article-title":"Stereotactic body radiotherapy in oligometastatic cervical cancer (MITO-RT2\/RAD study): A collaboration of MITO, AIRO GYN, and MaNGO groups","volume":"32","author":"Macchia","year":"2022","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ijrobp.2025.03.032_bib0033","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: A European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625002627?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625002627?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:33:10Z","timestamp":1777955590000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301625002627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0360301625002627"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.03.032","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Oligometastatic Parenchymal Lesions in Ovarian Cancer With Stereotactic Ablative Radiation Therapy: A Multicenter Prospective Phase 2 Trial (MITO RT3\/RAD)","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.03.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}